Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute lymphoblastic leukemia.
Hoelzer D, Gökbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van Dongen JJ, Szczepański T. Hoelzer D, et al. Among authors: appelbaum fr. Hematology Am Soc Hematol Educ Program. 2002:162-92. doi: 10.1182/asheducation-2002.1.162. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446423 Review.
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Sievers EL, et al. Among authors: appelbaum fr. J Clin Oncol. 2001 Jul 1;19(13):3244-54. doi: 10.1200/JCO.2001.19.13.3244. J Clin Oncol. 2001. PMID: 11432892 Clinical Trial.
Acute myeloid leukemia.
Appelbaum FR, Rowe JM, Radich J, Dick JE. Appelbaum FR, et al. Hematology Am Soc Hematol Educ Program. 2001:62-86. doi: 10.1182/asheducation-2001.1.62. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722979 Review.
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Larson RA, et al. Among authors: appelbaum fr. Leukemia. 2002 Sep;16(9):1627-36. doi: 10.1038/sj.leu.2402677. Leukemia. 2002. PMID: 12200674 Clinical Trial.
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR. Larson RA, et al. Among authors: appelbaum fr. Cancer. 2005 Oct 1;104(7):1442-52. doi: 10.1002/cncr.21326. Cancer. 2005. PMID: 16116598 Free article.
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR. Walter RB, et al. Among authors: appelbaum fr. Blood. 2007 May 15;109(10):4168-70. doi: 10.1182/blood-2006-09-047399. Epub 2007 Jan 16. Blood. 2007. PMID: 17227830 Free PMC article.
Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children.
Eden T, Pieters R, Richards S; Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Eden T, et al. Br J Haematol. 2010 Jun;149(5):722-33. doi: 10.1111/j.1365-2141.2010.08148.x. Epub 2010 Mar 16. Br J Haematol. 2010. PMID: 20331462 Free article. Review.
903 results